You are here

  • Home
  • Archive
  • Volume 82, Issue 4
  • Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Citation Tools

Article menu

Download PDFPDF

Letter
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dougados M, Charles-Schoeman C, Szekanecz Z, et al
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Annals of the Rheumatic Diseases 2023;82:575-577.